Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
19 March 2019 | Story Dr Cinde Greyling
Dr Mutana and Prof Mukwada
Many people enjoy spending time in the mountainous Drakensberg region. Prof Geofrey Mukwada’s involvement with the UFS Afromontane Research Unit (ARU) sparked an interest in sustainable tourism in the area. Pictured here are Dr Sarudzai Mutana with Prof Mukwada.

Not only is the Qwaqwa Campus situated in a beautiful region – its researchers also contribute to keeping the area pristine. Recent research by Prof Geofrey Mukwada and his PhD student, Dr Sarudzai Mutana, focused on indicators monitoring sustainable tourism development in the Drakensberg region.

Dr Mukwada is an Associate Professor in the Department of Geography on the University of the Free State (UFS) Qwaqwa Campus. 

Our majestic mountains are fragile

Many people enjoy spending time in the mountainous Drakensberg region – either as adventure seekers exploring the many trails, or just relaxing and reconnecting with nature. Prof Mukwada’s involvement with the UFS Afromontane Research Unit (ARU) sparked an interest in sustainable tourism in the area. “Mountains are fragile but attractive environments which continue to attract tourists,” he said. “Tourism is one of the major business sectors in the Drakensberg region, with promising growth opportunities and proving to be an anchor of green economy in the future – if practiced correctly.” Unfortunately, the issue of monitoring sustainable tourism has not been widely researched in African mountains. 

According to international standards

“We specifically looked at the Global Sustainable Tourism Criteria (GSTC), which is an international best-practice framework to help destinations monitor and ensure that tourism is developed in a responsible manner,” Prof Mukwada explained. “South Africa’s Manual for Responsible Tourism was designed according to some of the recommendations of the GSTC. But we found that, while the tourism and hospitality operators in the Drakensberg region appreciates the need to monitor and ensure sustainable tourism in the area, there is limited use of indicators as a tool for monitoring.” 

Forward together

There are competing demands between land-use and development practices and alternatives in the region – unless the focus shifts to sustainable practices, the short-term gains could be followed by dire consequences. “We suggest an integrated monitoring of tourism development, with a pro-poor focus that involves more local community leaders. Going forward, we would like to see the industry adopt the indicators proposed in our study.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept